MicroRNA in prostate cancer

Clinica Chimica Acta

Volumn 451, Issue , 2015, Pages 154-160

  Khanmi, Kasomva ^a   Ignacimuthu, Savarimuthu ^a,b   Paulraj, Michael Gabriel ^a  

^a LOYOLA COLLEGE   (India)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Androgen; MicroRNA (miRNA); Post transcription; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; MICRORNA; MICRORNA 145; MICRORNA 181; MICRORNA 18A; MICRORNA 205; MICRORNA 218; MICRORNA 23B; MICRORNA 296 5P; MICRORNA 29B; MICRORNA 429; MICRORNA 497; MICRORNA 940; UNCLASSIFIED DRUG;

CANCER GROWTH; CELL CYCLE REGULATION; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; RNA ANALYSIS; SIGNAL TRANSDUCTION; CELL CYCLE; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS;

CELL CYCLE; CELL PROLIFERATION; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84953297149     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.09.022     Document Type: Review

References (87)

1. American Cancer Society Cancer Facts & Figures 2015 2015, American Cancer Society, Atlanta.
2. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2015. CA Cancer J. Clin. 2015, 65:5-29.
3. Wang L., Li B., Lei L., Wang T. MicroRNA-497 Suppresses Proliferation and Induces Apoptosis in Prostate Cancer Cells. Asian Pac. J. Cancer Prev. 2013, 14(6):3499-3502.
4. Narzorow P.V., Reinsbach S.E., Muller A., Nicot N., Philippidou D., Vallar L., et al. Interplay of microRNAs, transcription factors and target genes: linking dynamic expression changes to function. Nucleic Acids Res. 2013, 41(5):2817-2831.
5. Cellini F., Morganti A.G., Genovesi D., Silvestris N., Valentini V. Role of MicroRNA in response to ionizing radiations: evidences and potential impact on clinical practice for radiotherapy. Molecules 2014, 19:5379-5401.
6. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
7. Liu C. MicroRNA regulation of prostate cancer stem/progenitor cells and prostate cancer development. UT GSBS Dissertations and Theses (Open Access) 2012, 236.
8. Tay Y., Zhang J., Thomson A.M., Lim B., Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008, 455:1124-1128.
9. Kurisetty V.V., Lakshmanswamy R., Damodaran C. Pathogenic and therapeutic role of miRNAs in breast cancer. Front. Biosci. 2014, 19:1-11.
10. Jin M., Zhang T., Liu C., Badeaux M.A., Liu B., Liu R., et al. MiRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells. Cancer Res. 2014, 10.1158/0008-5472.CAN-14-0404.
11. DeVere White R.W., Vinall R.L., Tepper C.G., Shi X.B. MicroRNAs and their potential for translation in prostate cancer. Urol. Oncol. 2009, 27:307-311.
12. Chiosea S., Jelezcova E., Chandran U., Acquafondata M., McHale T., Sobol R.W., et al. Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am. J. Pathol. 2006, 169:1812-1820.
13. Pang Y., Young Charles Y.F., Yuan H. MicroRNAs and prostate cancer. Acta Biochim. Biophys. Sin. 2010, 42:363-369.
14. Liu X., Chen X., Yu X., Tao Y., Bode A.M., Dong Z., et al. Regulation of microRNAs by epigenetics and their interplay involved in cancer. J. Exp. Clin. Cancer Res. 2013, 32:96.
15. Lo U.G., Yang D., Hsieh J.T. The role of microRNAs in prostate cancer progression. Translat. Androl. Urol. 2013, 2(3):228-241.
16. Hassan O., Ahmad A., Sethi S., Sarka F.H. Recent updates on the role of microRNAs in prostate cancer. J. Hematol. Oncol. 2012, 5:9.
17. Shi X.B., Xue L., Yang J., Ma A.H., Zhao J., Xu M., et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19983-19988.
18. Hsu T.I., Hsu C.H., Lee K.H., Lin J.T., Chen C.S., Chang K.C., et al. MicroRNA-18a is elevated in prostate cancer and promotes tumorigenesis through suppressing STK4 in vitro and in vivo. Oncogenesis 2014.
19. Porkka K.P., Pfeiffer M.J., Waltering K.K., Vessella R.L., Tammela Teuvo L.J., Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007, 67:6130-6135.
20. Srivastava A., Goldberger H., Dimtchev A., Ramalinga M., Chijioke J., Marian C., et al. MicroRNA profiling in prostate cancer - the diagnostic potential of urinary miR-205 and miR-214. PLoS One 2013, 8(10).
21. Vidal A., Koff A. Cell-cycle inhibitors: three families united by a common cause. Gene 2000, 247:1-15.
22. Stevaux O. Dyson NJ.A revised picture of the E2F transcriptional network and RB function. Curr. Opin. Cell Biol. 2002, 14:684-691.
23. Dimova D.K., Dyson N.J. The E2F transcriptional network: old acquaintances with new faces. Oncogene 2005, 24:2810-2826.
24. Alao J.A. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol. Cancer 2007, 6:24.
25. Dong Q., Meng P., Wang T., Qin W., Qin W., Wang F., et al. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One 2010, 5.
26. Elizabeth A.M., Caldon C.E., Barraclough J., Stone A., Sutherland R.L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 2011, 11:558-572.
27. Wang L.N., Chen W.W., Zhang J., Li C.Y., Liu C.Y., Xue J., et al. The miRNA let-7a1 inhibits the expression of insulin-like growth factor 1 receptor (IGF1R) in prostate cancer PC-3 cells. Asian J. Androl. 2013, 15:753-758.
28. Watahiki A., Wang Y., Morris J., Dennis K., O'Dwyer H.M., Gleave M., et al. MicroRNAs associated with metastatic prostate cancer. PLoS One 2011, 6.
29. Zheng D., Radziszewska A., Woo P. MicroRNA 497 modulates interleukin 1 signalling via the MAPK/ERK pathway. FEBS Lett. 2012, 586:4165-4172.
30. Luo M., Shen D., Zhou X., Chen X., Wang W. MicroRNA-497 is potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor. Surgery 2013, 12:751-759.
31. Ozen M., Creighton C.J., Ozdemir M., Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008, 27:1788-1793.
32. Sachdeva M., Zhu S.M., Wu F.T., Wu H.L., Walia V., Kumar S., et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3207-3212.
33. Sachdeva M., Mo Y.Y. MiR-145-mediated suppression of cell growth, invasion and metastasis. Am. J. Transl. Res. 2010, 2:170-180.
34. Cho W.C., Chow A.S., Au J.S. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol. 2011, 8:125-131.
35. Wach S., Nolte E., Szczyrba J., Stohr R., Hartmann A., Orntoft T., et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int. J. Cancer 2012, 130:611-621.
36. Law P.T., Ching A.K., Chan A.W., Wong Q.W., Wong C.K., To K.F., et al. MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis 2012, 33:1134-1141.
37. Hellawell G.O., Turner G.D., Davies D.R., Poulsom R., Brewster S.F., Macaulay V.M. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 2002, 62:2942-2950.
38. Karan D., Lin F.C., Bryan M., Ringel J., Moniaux N., Lin M.F., et al. Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int. J. Oncol. 2003, 23:1365-1371.
39. Thomsen M.K., Ambroisine L., Wynn S., Cheah K.S., Foster C.S., Fisher G., et al. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res. 2010, 70:979-987.
40. Wafa L.A., Cheng H., Plaa N., Ghaidi F., Fukumoto T., Fazli L., et al. Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression. Int. J. Cancer 2012, 130:2835-2844.
41. Wang C., Tao W., Ni S., Chen Q., Zhao Z., Ma L., et al. Tumor-suppressive microRNA-145 induces growth arrest by targeting SENP1 in human prostate cancer cells. Cancer Sci. 2015, 106(4):375-382.
42. Cheng J., Wang D., Wang Z., Yeh E.T. SENP1 enhances androgen receptordependent transcription through desumoylation of histone deacetylase 1. Mol. Cell. Biol. 2004, 24:6021-6028.
43. Cheng J., Bawa T., Lee P., Gong L., Yeh E.T. Role of desumoylation in the development of prostate cancer. Neoplasia 2006, 8:667-676.
44. Majid S., Dar A.A., Saini S., Arora S., Shahryari V., Zaman M.S., et al. MicroRNA-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res. 2012, 72(24):6435-6446.
45. Ouyang Y., Gao P., Zhu B., Chen X., Lin F., Wang X., Wei J., Zhang H. Downregulation of microRNA-429 inhibits cell proliferation by targeting p27Kip1 in human prostate cancer cells. Mol. Med. Rep. 2015, 11(2):1435-1441.
46. Lu K.P., Zhou X.Z. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat. Rev. Mol. Cell Biol. 2007, 8:904-916.
47. Lee K.H., Lin F.C., Hsu T.I., Lin J.T., Guo J.H., Tsai C.H., et al. MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1. Biochim. Biophys. Acta 1843, 2014:2055-2066.
48. Tong S.J., Liu J., Wang X., Qu L.X. MicroRNA-181 promotes prostate cancer cell proliferation by regulating DAX-1 expression. Exp. Ther. Med. 2014, 8:1296-1300.
49. Nishikawa R., Goto Y., Sakamoto S., Chiyomaru T., Enokida H., Kojima S., et al. Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer. Cancer Sci. 2014, 105:802-811.
50. Alajez N.M., Lenarduzzi M., Ito E., Hui A.B., Shi W., Bruce J., et al. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 2011, 71:2381-2391.
51. Tomasetto C., Moog-Lutz C., Regnier C.H., Schreiber V., Basset P., Rio M.C. Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains. FEBS Lett. 1995, 373:245-249.
52. Keicher C., Gambaryan S., Schulze E., Marcus K., Meyer H.E., Butt E. Phosphorylation of mouse LASP-1 on threonine 156 by cAMP- and cGMP-dependent protein kinase. Biochem. Biophys. Res. Commun. 2004, 324:308-316.
53. Li B., Zhuang L., Trueb B. Zyxin interacts with the SH3 domains of the cytoskeletal proteins LIM-nebulette and lasp-1. J. Biol. Chem. 2004, 279:20401-20410.
54. Rachlin A.S., Otey C.A. Identification of palladin isoforms and characterization of an isoform-specific interaction between lasp-1 and palladin. J. Cell Sci. 2006, 119:995-1004.
55. Steele R., Mott J.L., Ray R.B. MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells. Genes Cancer 2010, 1:381-387.
56. Peng R., Steele R., Newhall P., Nancy J.P., Toth K., Ray R.B. MiRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol. Cancer Ther. 2012, 11(5):1166-1173.
57. Hart M., Wach S., Nolte E., Szcyrba J., Menon R., Taubert H., et al. The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer. FEBS J. 2013, 280(9):2105-2116.
58. Kojima S., Enokida H., Yoshino H., Itesako T., Chiyomaru T., Kinoshita T., et al. The tumor suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J. Hum. Genet. 2014, 59(2):78-87.
59. Dasgupta S., Wasson L.M., Rauniyar N., Prokai L., Borejdo J., Vishwanatha J.K. Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells. Oncogene 2009, 28(32):2860-2872.
60. Dasgupta S., Cushman I., Kpetemey M., Casey P.J., Vishwanatha J.K. Prenylated C17ORF37 induces filopodia formation to promote cell migration and metastasis. J. Biol. Chem. 2011, 289(9):25935-25946.
61. Rajendiran S., Parwani A.V., Hare R.J., Dasgupta S., Roby R.K., Vishwanatha J.K. MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1. Mol. Cancer 2014, 13:250.
62. Sempere L.F., Christensen M., Silahtaroglu A., Bak M., Heath C.V., Schwartz G., et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007, 67:11612-11620.
63. Childs G., Fazzari M., Kung G., Kawachi N., Brandwein-Gensler M., Mclemore M., et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am. J. Pathol. 2009, 174:736-745.
64. Wiklund E.D., Bramsen J.B., Hulf T., Dyrskjot L., Ramanathan R., Hansen T.B., et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int. J. Cancer 2011, 128:1327-1334.
65. Gregory P.A., Bracken C.P., Bert A.G., Goodall G.J. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008, 7:3112-3118.
66. Bhatnagar N., Li X., Padi S.K., Zhang Q., Tang M.S., Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 2010, 1.
67. Verdoodt B., Neid M., Vogt M., Kuhn V., Liffers S.T., Palisaar R.J., et al. MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int. J. Oncol. 2013, 43:307-314.
68. Wu H., Zhu S., Mo Y.Y. Suppression of Cell Growth and Invasion by miR-205 in Breast Cancer. Cell Res. 2009, 19:439-448.
69. Matsushima K., Isomoto H., Yamaguchi N., Inoue N., Machida H., Nakayama T., et al. MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J. Transl. Med. 2011, 9:30.
70. Jackson B.L., Grabowska A., Ratan H.L. MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers. BMC Cancer 2014, 14:930.
71. Kroiss A., Vincent S., Decaussin-Petrucci M., Meugneir E., Viallet J., Ruffion A., et al. Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. Oncogene 2015, 34(22):2846-2855.
72. Jalava S.E., Urbanucci A., Latonen L., Waltering K.K., Sahu B., Jänne O.A., et al. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene 2012, 31:4460-4471.
73. Xiaoping Y., Lynne B., Lih-Jen S., Dexiang G., Thomas W.F. MiR-125b regulation of androgen receptor signaling via modulation of the receptor complex co-repressor NCOR2. BioResearch 2012, 1:55-62.
74. Epis M.R., Giles K.M., Barker A., Kendrick T.S., Leedman P.J. MiR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J. Biol. Chem. 2009, 284:24696-24704.
75. Ribas J., Ni X., Haffner M., Wentzel E.A., Salmasi A.H., Chowdhury W.H., et al. MiR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009, 69:7165-7169.
76. Waltering K.K., Porkka K.P., Jalava S.E., Urbanucci A., Kohonen P.J., Latonen L.M., et al. Androgen regulation of micro-RNAs in prostate cancer. Prostate 2011, 71:604-614.
77. Varambally S., Cao Q., Mani R.S., Shankar S., Wang X., Ateeq B., et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322:1695-1699.
78. Cao P., Deng Z., Wan M., Huang W., Cramer S.D., Xu J., et al. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β. Mol. Cancer 2010, 9:108.
79. Baek D., Villen J., Shin C., Camargo F.D., Gygi S.P., Bartel D.P. The impact of microRNAs on protein output. Nature 2008, 455:64-71.
80. Selbach M., Schwanhausser B., Thierfelder N., Fang Z., Khanin R., Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455:58-63.
81. Sikand K., Slaibi J.E., Singh R., Slane S.D., Shukla G.C. MiR 488* inhibits androgen receptor expression in prostate carcinoma cells. Int. J. Cancer 2011, 129:810-819.
82. Reis S.T., Timoszczuk L.S., Jose P.J., Viana N., Silva I.A., Dip N., et al. The role of micro RNAs let7c, 100 and 218 expression and their target RAS, C-MYC, BUB1, RB, SMARCA5, LAMB3 and Ki-67 in prostate cancer. Clinics 2013, 68(5):652-657.
83. Li T., Li D., Sha J.J., Sun P., Huang Y.R. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem. Biophys. Res. Commun. 2009, 383:280-285.
84. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. 2008, 105:10513-10518.
85. Wiggins J.F., Ruffino L., Kelnar K., Omotola M., Patrawala L., Brown D., et al. Development of a lung cancer therapeutic based on the tumour suppressor microRNA-34. Cancer Res. 2010, 70:5923-5930.
86. Trang P., Medina P.P., Wiggins J.F., Ruffino L., Kelnar K., Omotola M., et al. Regression of murine lung tumours by the let-7 microRNA. Oncogene 2009, 29:1580-1587.
87. Bader A.G., Brown D., Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010, 70:7027-7030.